RESULT REVIEW

BUY
TP: Rs 2,003 | ⮝ 19%

SUN PHARMA | Pharmaceuticals | 06 November 2025

In-line result; global innovative portfolio growth to continue

- **Sales/EBITDA/PAT was 2%/3%-2% above our estimates. Gross Margin was 40 bps lower and EBITDA Margin was 30 bps higher than estimates**
- **SG&A cost expected to rise with the launch of Unloxcyt. Hence, R&D expense contribution guided at a lower end of 6-8%.**
- **Due to a strong innovative portfolio, we ascribe PE of 34x on Sep'27 roll forward, slightly higher than 1YF mean PE of 32x**

Foram Parekh
Research Analyst
research@bobcaps.in

In-line earnings – Sales grew by 9% YoY to Rs 144 bn, driven by 11% YoY growth in the domestic region, 23% YoY growth in ROW region, 15.7% YoY growth in the EMs and flattish growth in the US region which was offset by 17% decline in the API sales. Global Innovative sales grew by 16% YoY sales of USD 333 mn, contributing 20% of total sales. Healthy growth in innovative sales resulted in 79.4% Gross margin and 28.3% EBITDA margin. During the quarter, Checkpoint acquisition led to an increase in borrowings, resulting in 44% rise in the interest cost and tax rate to 27.6%, resulting in 7% YoY decline in PAT to Rs 27bn.

US sales driven by innovative portfolio - US sales reported flat to Rs 43.2 bn, driven by innovative sales that offset YoY decline in gRevlimid. US innovative sales grew strongly, drives by the launch of Leqselvi and steady demand for Ilumya, Cequa, and Odomzo, which exceeded US generic sales. Going forward in H2FY26, there will be no gRevlimid sales; however, this impact is expected to be offset by the launch of Unloxcyt, which is pending USFDA approval under Sun's label, along with the planned filing of Ilumya for the psoriatic arthritis indication.

ROW region growth driven by generics and innovative product - ROW region reported sales 15% above our estimates, with organic growth (ex one-offs) of 22.7% YoY to Rs20.4 bn. The growth was driven by both generic and innovative products, including Ilumya that has been launched in 35 countries.

Domestic region continues to grow in double digits – Domestic sales was in line with our estimates and grew 11% YoY to Rs 47.3bn. The growth continues to be driven by volume due to sustaining leadership position by Rx across 13 therapies and 9 new launches during the quarter vs price-led growth in IPM. Going forward, Sun would participate in the first wave of Semaglutide LOE.

Maintain BUY - We believe the 100% tariff threat on branded products is behind for SUN. At CMP, the stock is trading at 29x PE on Sep'27 roll forward basis. Due to healthy cash balance and strong innovative portfolio, we ascribe a PE of 34x, slightly higher than 1year forward mean PE of 32x to arrive at a PT of Rs 2003.

Key changes

Target	Rating
◀ ▶	◀ ▶

Ticker/Price	SUNP IN/Rs 1,690
Market cap	US$ 45.7bn
Free float	45%
3M ADV	US$ 42.7mn
52wk high/low	Rs 1,910/Rs 1,548
Promoter/FPI/DII	54%/16%/20%

Source: NSE | Price as of 4 Nov 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	525,785	568,655	621,929
EBITDA (Rs mn)	153,869	164,843	188,139
Adj. net profit (Rs mn)	118,260	115,328	133,166
Adj. EPS (Rs)	49.3	48.1	55.5
Consensus EPS (Rs)	49.3	48.4	55.2
Adj. ROAE (%)	16.9	14.9	15.2
Adj. P/E (x)	34.3	35.2	30.4
EV/EBITDA (x)	27.9	26.5	23.8
Adj. EPS growth (%)	16.2	(2.5)	15.5

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

Financial Highlights

Fig 1 – Quarterly Snapshot

(Rs mn)	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)	H1FY25	H1FY26	YoY (%)	FY25	FY26E	FY27E	FY28E
Net Sales	1,44,783	1,32,914	8.9	1,38,514	4.5	2,59,441	2,83,297	9.2	5,25,785	5,68,655	6,21,929	6,80,513
Total Expenses	1,03,817	94,805	9.5	97,788	6.2	1,84,752	2,01,605	9.1	3,71,916	4,03,812	4,33,790	4,71,249
(%) of net sales	72	71		71		71	71		71	71	70	69
Raw material consumed	29,827	26,942	10.7	28,148	6.0	53,696	57,975	8.0	1,04,467	1,13,731	1,24,386	1,36,103
(%) of net sales	20.6	20		20		20.7	20.5		19.9	20.0	20.0	20.0
Staff cost	27,648	24,777	11.6	28,017	(1.3)	49,323	55,665	12.9	99,731	1,07,863	1,15,057	1,25,895
(%) of net sales	19.1	18.6		20.2		19	20		19	19	19	19
R&D cost	7,827	7,929	(1.3)	9,029	(13.3)	15,691	16,856	7.4	32,484	34,119	37,316	40,831
(%) of net sales	5.4	6.0		6.5		6.0	5.9		6.2	6.0	6.0	6.0
SG&A	38,516	35,157	9.6	32,595	18.2	66,042	71,110	7.7	1,35,234	1,48,100	1,57,031	1,68,421
(%) of net sales	26.6	26.5		23.5		25.5	25.1		25.7	26.0	25.2	24.7
EBITDA	40,966	38,109	7.5	40,726	0.6	74,689	81,692	9.4	1,53,869	1,64,843	1,88,139	2,09,264
PBT	37,371	34,698	7.7	37,617	(0.7)	69,438	74,989	8.0	1,45,470	1,53,438	1,77,276	1,98,969
Less: Taxation	10,305	5,672		8,702		11,195	19,007	69.8	27,720	38,620	44,620	50,080
PAT	27,066	29,026	(6.8)	28,676	(5.6)	57,982	55,742	(3.9)	1,17,750	1,14,818	1,32,656	1,48,888
Less: Minority Interest	121	(95)		240		261	361	38.4	(511)	(511)	(511)	(511)
Exceptional items	0	1,281		(5,890)		776	(5,890)	(858.6)	(8,634)	0	0	0
PAT attributable to shareholders	26,945	30,402	(11.4)	22,786	18.3	58,758	49,731	(15.4)	1,09,626	1,15,328	1,33,166	1,49,399
Key Ratios (%)												
Gross Margin	79.4	79.7	(33bps)	79.7	(28bps)	79.3	79.5	23	80.1	80.0	80.0	80.0
EBITDA Margin	28.3	28.7	(38bps)	29.4	(111bps)	28.8	28.8	5	29.3	29.0	30.3	30.8
Tax / PBT	27.6	16.3	1,123bps	23.1	444bps	16.1	25.3	922	19.1	25.2	25.2	25.2
NPM	18.7	21.8	(314bps)	20.7	(201bps)	22.3	19.7	(267)	22.4	20.2	21.3	21.9
EPS (Rs)	13.0	12.7	2.8	9.5	37.1	24.5	22.5	(8.0)	45.7	48.1	55.5	62.3

Source: Company, BOBCAPS Research

Fig 2 – Segmental Revenue

(Rs mn)	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)	H1FY25	H1FY26	YoY (%)	FY25	FY26E	FY27E	FY28E
Formulation	1,39,418	1,27,078	9.7	1,31,930	5.7	2,46,926	2,71,348	9.9	4,97,420	5,36,950	5,88,421	6,45,075
Domestic	47,348	42,652	11.0	47,211	0.3	84,097	94,559	12.4	1,69,230	1,82,814	2,00,138	2,19,190
Exports	92,070	84,426	9.1	84,719	8.7	1,62,829	1,76,789	8.6	3,28,190	3,54,136	3,88,283	4,25,885
US	43,288	43,274	0.0	40,452	7.0	82,169	83,740	1.9	1,62,403	1,74,735	1,94,882	2,17,324
EM & ROW	48,782	41,152	18.5	44,267	10.2	80,661	93,049	15.4	1,65,787	1,79,401	1,93,401	2,08,561
EM	28,367	24,519	15.7	22,561	25.7	48,214	50,928	5.6	94,160	1,02,633	1,11,870	1,21,939
ROW	20,415	16,633	22.7	17,340	17.7	32,446	37,755	16.4	71,627	76,767	81,530	86,622
APIs and others	4,635	5,564	(16.7)	5,930	(21.8)	10,961	10,565	(3.6)	22,994	25,547	26,773	28,068
Net Sales	1,44,052	1,32,642	8.6	1,37,860	4.5	2,57,887	2,81,913	9.3	5,20,413	5,62,497	6,15,194	6,73,143
OOI	731	272	NA	654	NA	1,554	1,385	(10.9)	5,372	6,158	6,735	7,370
Revenue	1,44,783	1,32,914	8.9	1,38,514	4.5	2,59,441	2,83,297	9.2	5,25,785	5,68,655	6,21,929	6,80,513

Source: Company, BOBCAPS Research

Financials in Charts

Fig 3 – Revenue growth declined due to lower API sales



Source: Company, BOBCAPS Research

Fig 4 – US revenue sales decreased on lower Revlimid sales



Source: Company, BOBCAPS Research

Fig 5 – Global specialty sales increased with launch of Leqselvi



Source: Company, BOBCAPS Research

Fig 6 – EBITDA growth lowered with higher SG&A spend on launch product



Source: Company, BOBCAPS Research

Fig 7 – EBITDA margin sequentially declined given the higher spend on Leqselvi



Source: Company, BOBCAPS Research

Fig 8 – PAT lowered due to higher interest cost and tax rate



Source: Company, BOBCAPS Research

Earnings Call Highlights

Management Guidance:

- **Tax rate:** ETR expected to be around 25% for FY26.
- **R&D expense:** Expected to be at the lower end of the 6-8% guidance for FY26.

R&D and pipeline updates

- **R&D:** R&D spend for Q2FY26 was Rs 7,827 mn (5.4% of sales). Innovative R&D accounted for 38% of total R&D spend and was 10% of global innovative medicine sales.
- **Ilumya:** Management plans a sBLA filing during H2FY26. Illumya is commercially available across 35 markets and Rx growth is expected to continue.
- **Unloxcyt** (Checkpoint acquisition): SUNP is awaiting the FDA decision on updated labeling and remains on track to launch in the US in H2FY26.
- **Leqselvi:** Launched in the US in Q2; improved uptake expected going forward.
- **GLP-1:** Management confirmed that a global phase-2 diabetes study is ongoing for GL0034; early data will be presented shortly.

India business

- **Sales:** India formulation sales in Q2FY26 were Rs 47,348 mn, representing 32.9% of consolidated sales.
- **Growth drivers:** India growth was driven by volumes and new product launches.
- **Product launches:** The company launched nine new products in India during the quarter and outperformed IPM across major therapy areas.
- **Rx volumes:** Rx volumes remain strong and place Sun Pharma to No. 1 spot in several doctor categories.

US business

- **Formulation sales:** Total U.S. formulation sales declined by 4.1% to $496mn in Q2FY26, accounting for ~30% of consolidated sales.
- **US generics:** Generics business was weaker, primarily due to additional competition on certain products and lower sales of lenalidomide YoY.
- **Innovative medicines** in the US (Illumya, Cequa, and Odomzo) outperformed generics, with innovative medicine sales surpassing generics in the quarter.
- **New product launches:** Three new generic launches in the quarter. SUNP launched Leqselvi with expectations of improving uptake over time.

Emerging markets (EM) and ROW:

- **EM Performance:** EM revenues were $325 mn in Q2FY26, up 10.9% YoY (8% on a cc basis), and accounted for 19.7% of consolidated revenue driven by South Africa and Brazil markets.

- **ROW performance:** ROW revenues were $234mn, up 17.7% YoY, and accounted for ~14.2% of consolidated revenue.
- **ROW growth:** Growth in ROW was broad-based across generics and innovative medicines.

Global Innovative Medicines (Specialty)

- **Sales:** Global Innovative Medicines sales were $313 mn in Q2FY26, up 16.4% YoY.
- **Performance:** Innovative medicine sales in the US exceeded generics during the quarter. Illumya is now commercialized in 35 markets.
- **Notable contributors:** Illumya (the largest brand), Cequa, Odomzo and the newly launched Leqselvi. Cequa continues to grow despite additional generic entrants.
- **Market share:** SUNP has a market share of over 60% in Odomzo in the European market.

Other highlights:

- **Intangible assets** rose materially due to the Checkpoint acquisition (Checkpoint intangible ~US$471mn) and Leqselvi moving from intangibles under development into intangible assets.
- **Tariffs:** Management described the 100% tariff proposal on patented products as paused and uncertain. The company believes generics are currently excluded, but final outcomes remain unclear.

Valuation Methodology

Sun Pharma broadly reported in line set of earnings on all fronts. Global innovative sales grew by 16% YoY to USD 333 mn, driven by the launch of Leqselvi and uptick in key products like Ilumya, Cequa and Odomzo. Domestic sales continue to surpass IPM and grows in double digits, driven by volume and new product launches. ROW &EMs too reported healthy growth, driven by both generics and innovative portfolio. Ilumya sales to remain in upward trajectory as IL23 inhibitor continues to grow amidst rising competition.

Going forward, growth in specialty sales is expected to grow with the launch of Unloxcyt in H2FY26 and a pickup in newly launched Leqselvi in H2FY26. However, in the long run, Sun's global specialty growth is expected to be driven by the psoriatic arthritis indication for Ilumya and the commercialization of MM-II with its partner, for which Sun has received fast-track approval. Domestic sales, too, are expected to grow in double digits due to sustenance of leadership position across 13 therapies and participation in Semaglutide LOE in the first wave. EMs and ROW regions would also maintain the momentum with a healthy traction in Ilumya launch across 35 countries. During the quarter, R&D contribution was lower at 5.4% and is expected to sustain around 6%; thus enabling SUNP to increase EBITDA margin to 30% and beyond from FY27E.

We believe the 100% tariff threat on branded products is behind for SUNP and the company has a risk-mitigation strategy by having facilities in the US. Hence, we increase EPS marginally in FY28E. Factoring in the above positive, we model in sales/EBITDA/PAT CAGR of 9%/13%/14%. At CMP, the stock is trading at 29x PE on Sep'27 roll forward basis. Due to healthy cash balance and a strong innovative portfolio, we ascribe PE of 34x, slightly higher than 1YF mean PE of 32x to arrive at TP of Rs 2,003.

Fig 9 – Actual Vs Estimates

(Rs mn)	Q2FY26A	Q2FY26E	Var. (%)	Cons. Est	Var. (%)
Revenue	1,44,783	1,41,640	2.2	1,41,840	2.1
EBITDA	40,966	39,659	3.3	39,517	3.7
EBITDA Margin (%)	28.3	28.0	29bps	27.9	43bps
PAT	26,945	27,492	(2.0)	29,325	(8.1)
EPS	13.0	11.5	13.7	12.1	7.3

Source: Company, BOBCAPS Research

Fig 10 – Revised Estimates

(Rs mn)	New			Old			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	5,68,655	6,21,929	6,80,513	5,64,062	6,10,227	6,57,317	0.8	1.9	3.5
EBITDA	1,64,843	1,88,139	2,09,264	1,60,622	1,82,964	1,97,083	2.6	2.8	6.2
EBITDA margin (%)	29.0	30.3	30.8	28.5	30.0	30.0	51bps	27bps	77bps
PAT	1,15,328	1,33,166	1,49,399	1,17,813	1,35,950	1,47,427	(2.1)	(2.0)	1.3
EPS (Rs)	48.1	55.5	62.3	49.1	56.7	61.5	(2.1)	(2.1)	1.3

Source: Company, BOBCAPS Research

Key risks

Key downside risks to our estimates:

- any regulatory hurdle affecting launch of Unloxcyt
- continued regulatory hindrances to plants under USFDA scrutiny
- deterioration in the US generic pricing environment

Peer Comparison

Fig 11 – Peer analysis of domestic segment

Companies	CMP (Rs)	Market cap (Rs mn)	Domestic FY25 Sales (Rs mn)	Domestic sales as of total sales (%)	MR Strength	Productivity per MR (Rs mn)	Chronic (%)	EPS			PE			FY28		
								FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	ROCE	EV/ EBITDA	PEG
Abbott	29,360	6,22,432	64,092	98	3,659	17.1	75	721.7	835.7	941.9	40.7	35.1	31.2	45.1	28.6	3.6
Ajanta Pharma	2,611	3,26,338	46,481	31	3,600	4.0	65	79.6	88.0	98.5	32.8	29.7	26.5	28.2	19.0	2.9
Alembic	961	1,89,258	66,720	35	5,500	4.3	54	36.9	45.0	53.8	26.0	21.3	17.9	18.6	11.1	1.8
Alkem	5,664	6,79,680	1,29,645	69	12,500	7.2	15	198.0	168.8	194.4	28.6	33.6	29.1	22.9	16.7	3.0
Cipla	1,503	12,14,666	2,75,476	42	11,512	10.1	62	62.1	63.9	70.3	24.2	23.5	21.4	17.7	17.3	2.8
Dr.Reddy's	1,200	10,02,000	3,26,439	16	7,400	7.3	66	60.8	60.4	71.1	19.7	19.9	16.9	16.9	11.9	2.2
Emcure Pharma	1,325	2,51,693	78,960	46	4,100	8.9	65	46.8	58.6	69.8	28.3	22.6	19.0	29.9	10.8	1.7
Eris	1,601	5,05,916	28,936	87	3,469	7.2	82	40.9	53.8	66.8	39.1	29.8	24.0	24.2	14.0	1.6
GSK	2,659	4,49,287	37,492	99	3,100	11.9	40	60.4	68.5	73.7	44.0	38.8	36.1	44.6	27.1	6.4
Lupin	1,997	9,12,629	2,27,079	33	10,000	7.6	70	83.5	97.3	107.4	23.9	20.5	18.6	18.6	10.8	2.0
Mankind	2,370	9,78,604	1,22,074	87	17,700	6.0	63	50.8	65.5	80.7	46.6	36.2	29.3	18.6	18.2	3.1
Sun pharma	**1,690**	**40,56,000**	**5,25,784**	**32**	**15,000**	**11.3**	**78**	**48.1**	**55.5**	**62.3**	**35.2**	**30.4**	**27.1**	**15.7**	**22.8**	**2.9**
Torrent Pharma	3,575	12,08,350	1,15,161	56	6,400	10.0	76	72.7	86.5	101.1	49.2	41.3	35.3	30.8	21.1	2.6

Source: Company, BOBCAPS Research

Valuation Bands

Fig 12 – 1YF P/E band



Source: Company, BOBCAPS Research

Fig 13 – 1YF EV/EBITDA band



Source: Company, BOBCAPS Research

Fig 14 – 1YF P/B band



Source: Company, BOBCAPS Research

Fig 15 – 1YF EV/sales band



Source: Company, BOBCAPS Research

Fig 16 – Sun pharma Vs Nifty pharma



Source: Company, BOBCAPS Research

Fig 17 – Sun pharma 1YF premium/discount to Nifty 50



Source: Company, BOBCAPS Research

BOBCAPS
TRUST | INNOVATION | EXCELLENCE

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	**484,969**	**525,785**	**568,655**	**621,929**	**680,513**
EBITDA	129,884	153,869	164,843	188,139	209,264
Depreciation	25,566	25,736	26,977	28,279	29,647
EBIT	104,317	128,133	137,866	159,860	179,617
Net interest inc./(exp.)	(2,385)	(2,314)	(1,303)	(1,040)	(843)
Other inc./(exp.)	13,542	19,650	16,875	18,456	20,194
Exceptional items	0	0	0	0	0
EBT	115,474	145,470	153,438	177,276	198,969
Income taxes	14,395	27,720	38,620	44,620	50,080
Extraordinary items	(5,305)	(8,634)	0	0	0
Min. int./Inc. from assoc.	(721)	(511)	(511)	(511)	(511)
Reported net profit	**96,496**	**109,626**	**115,328**	**133,166**	**149,399**
Adjustments	5,305	8,634	0	0	0
Adjusted net profit	**101,801**	**118,260**	**115,328**	**133,166**	**149,399**

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	56,533	61,843	65,123	71,905	78,678
Other current liabilities	36,579	44,373	44,565	44,777	45,009
Provisions	57,715	66,202	72,357	79,127	86,575
Debt funds	32,737	23,622	18,612	14,855	12,037
Other liabilities	0	0	0	0	0
Equity capital	2,399	2,399	2,399	2,399	2,399
Reserves & surplus	669,546	722,460	821,897	930,712	1,052,835
Shareholders' fund	671,945	724,860	824,297	933,112	1,055,234
Total liab. and equities	**855,508**	**920,899**	**1,024,953**	**1,143,776**	**1,277,534**
Cash and cash eq.	98,919	116,208	184,646	263,698	343,146
Accounts receivables	112,494	130,461	129,311	139,721	152,882
Inventories	98,683	102,433	101,267	102,235	111,865
Other current assets	102,335	95,956	95,956	95,956	95,956
Investments	150,258	183,538	207,080	232,975	261,462
Net fixed assets	109,090	100,359	108,106	103,294	98,288
CWIP	53,539	66,440	73,084	80,392	88,431
Intangible assets	130,191	125,503	125,503	125,503	125,503
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	**855,508**	**920,899**	**1,024,953**	**1,143,775**	**1,277,534**

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	**132,005**	**146,594**	**150,171**	**158,954**	**165,040**
Capital expenditures	(24,688)	(37,591)	(28,994)	(30,776)	(32,680)
Change in investments	(1,957)	(33,280)	(18,354)	(20,189)	(22,208)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	**(26,645)**	**(70,872)**	**(47,348)**	**(50,965)**	**(54,888)**
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(36,122)	(9,115)	(5,010)	(3,757)	(2,818)
Interest expenses	(2,385)	(2,314)	(1,303)	(1,040)	(843)
Dividends paid	(17,387)	(19,753)	(20,780)	(23,994)	(26,919)
Other financing cash flows	(7,810)	(39,624)	5,081	(145)	(124)
Cash flow from financing	**(63,703)**	**(70,805)**	**(22,011)**	**(28,937)**	**(30,704)**
Chg in cash & cash eq.	**41,657**	**4,916**	**80,811**	**79,052**	**79,448**
Closing cash & cash eq.	**98,919**	**103,835**	**184,646**	**263,698**	**343,146**

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	40.2	45.7	48.1	55.5	62.3
Adjusted EPS	42.4	49.3	48.1	55.5	62.3
Dividend per share	7.2	8.2	8.7	10.0	11.2
Book value per share	265.8	301.0	342.6	388.1	0.0

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	8.7	8.2	7.7	7.2	6.7
EV/EBITDA	32.6	27.9	26.5	23.8	21.9
Adjusted P/E	39.8	34.3	35.2	30.4	27.1
P/BV	6.4	5.6	4.9	4.4	

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	88.2	81.3	75.2	75.1	75.1
Interest burden (PBT/EBIT)	110.7	113.5	111.3	110.9	110.8
EBIT margin (EBIT/Revenue)	21.5	24.4	24.2	25.7	26.4
Asset turnover (Rev./Avg TA)	14.6	14.8	14.6	14.3	14.1
Leverage (Avg TA/Avg Equity)	1.3	1.3	1.3	1.2	1.2
Adjusted ROAE	16.1	16.9	14.9	15.2	15.0

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	10.5	8.4	8.2	9.4	9.4
EBITDA	6.7	18.5	7.1	14.1	11.2
Adjusted EPS	18.8	16.2	(2.5)	15.5	12.2
Profitability & Return ratios (%)					
EBITDA margin	26.8	29.3	29.0	30.3	30.8
EBIT margin	21.5	24.4	24.2	25.7	26.4
Adjusted profit margin	21.0	22.5	20.3	21.4	22.0
Adjusted ROAE	16.1	16.9	14.9	15.2	15.0
ROCE	15.1	16.4	14.5	15.8	15.7
Working capital days (days)					
Receivables	85	84	83	82	82
Inventory	77	70	65	60	60
Payables	205	207	209	211	211
Ratios (x)					
Gross asset turnover	1.3	1.3	1.4	1.4	1.5
Current ratio	2.7	2.6	2.8	3.1	3.3
Net interest coverage ratio	43.7	55.4	105.8	153.7	213.2
Adjusted debt/equity	(0.3)	(0.4)	(0.5)	(0.5)	(0.6)

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
Brand Name: **BOBCAPS**
Trade Name: **www.barodaetrade.com**
CIN: **U65999MH1996GOI098009**

Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months
BUY – Expected return >+15%
HOLD – Expected return from -6% to +15%
SELL – Expected return <-6%
Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): SUN PHARMA (SUNP IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification
The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers
BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK"**). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.